Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Fig. 4

Comparison of treatment related adverse events for different regimens in CheckMate 012 and CheckMate 067. Legend: The figure elaborates percent patients documented to have adverse events with different treatment regimens assessed in the CheckMate 012 and CheckMate 067 trials. Please note that some participants had more than one adverse event. No treatment associated deaths were reported till point of assessment in CheckMate 012 while 2 treatment related deaths in CheckMate 067 nivolumab group were reported > 100 days after discontinuation of therapy. Abbreviations: NIVO, nivolumab; IPI, ipilimumab; n, number of patients; X axis: treatment regimens, Y axis: percent patients relative to cohort size

Back to article page